Catalyst Pharmaceuticals
Preethi Sundaram, PhD, who joined Catalyst in July 2021, has more than 20 years’ experience leading, managing, and mentoring teams delivering lifesaving medicines to patients. Since 2005, Dr. Sundaram was employed in various positions at Sanofi spanning R&D and Medical Affairs, including as Global Clinical Research Director, International Development, Global Project Head, Multiple Therapeutic Area Programs, and more recently as Global Head Medical Operations, General Medicines Business Unit. In this most recent role, she led critical global medical operational functions, including the oversight of portfolio financials, delivery of key strategic and operational milestones, as well as being responsible for the leadership of portfolio management functions across all therapeutic areas (Diabetes, Cardiovascular, & Established products).
Prior to joining Sanofi, Dr. Sundaram held leadership positions at Abbott Labs and Covance. Prior to her industry tenure, Dr. Sundaram held clinical and faculty positions within academia and start-up environments in India, Australia, and the UK. Dr. Sundaram is an Optometrist by training with an Optometry degree from the Elite School of Optometry & Birla Institute of Technology & Science (India), and a Doctor of Philosophy in Optometry from Anglia Ruskin University (UK).
In addition, Dr. Sundaram holds a Bachelor of Arts in Psychology from the University of Madras (India) and an Executive Business Masters from the London Business School.
This person is not in any offices
Catalyst Pharmaceuticals
2 followers
Catalyst Pharmaceuticals is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, first- or best-in-class medicines for other rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.